Welcome to our dedicated page for Amesite SEC filings (Ticker: AMST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wondering whether Amesite’s AI business has the cash runway to keep innovating, or if executives have been buying shares? This page gathers every SEC disclosure—from an Amesite annual report 10-K simplified to each Amesite Form 4 insider transactions real-time—so you can stop searching EDGAR line by line.
Stock Titan’s AI reads the dense accounting notes and legal language for you. Need the latest Amesite quarterly earnings report 10-Q filing? Our system highlights revenue trends and R&D spend in plain English. Tracking governance? Get instant alerts when a new Amesite proxy statement executive compensation posts. Material news moves quickly; that’s why every Amesite 8-K material events explained section is summarized within seconds of filing.
Use cases:
- Spot patterns in Amesite insider trading Form 4 transactions before the market reacts.
- Compare product development costs quarter-over-quarter with Amesite earnings report filing analysis.
- Prepare questions for management calls by understanding Amesite SEC documents with AI.
Whether you monitor Amesite executive stock transactions Form 4 or dive deep into risk factors, our platform delivers clear, expert context, real-time updates, and AI-powered summaries that turn complex filings into actionable insight.
Amesite Inc. (AMST) reported a Section 16 filing showing that on 09/30/2025 the reporting person received 3,934 restricted stock units (RSUs) as deferred compensation for board service. Each RSU represents a contingent right to one share of common stock or a cash equivalent calculated using the closing price on the quarter end. The RSUs were issued in lieu of cash director fees and will be delivered upon completion of board service or earlier upon a change in control. After the transaction, the reporting person beneficially owns 61,912 shares indirectly through the Gilbert S. Omenn Revocable Trust. The Form 4 was executed by an attorney-in-fact on 10/02/2025.
George Parmer, a director of Amesite Inc. (AMST), was issued 3,934 restricted stock units (RSUs) on 09/30/2025 as deferred compensation in lieu of cash. Each RSU represents a contingent right to one share of AMST common stock or a cash equivalent, and the number of units was calculated using the closing share price on the last day of the quarter. The RSUs are payable upon completion of Mr. Parmer's board service or, if earlier, a change in control. Following this grant, Mr. Parmer beneficially owns 55,016 shares of AMST common stock. The units were reported with an indicated price of $0 because they represent deferred compensation, not a cash purchase.
Amesite Inc. (AMST) director J. Michael Losh was granted 4,754 restricted stock units (RSUs) on 09/30/2025 as deferred compensation in lieu of cash. Each RSU represents a contingent right to one share of AMST common stock or the cash equivalent. The RSUs were calculated using the closing share price on the last day of the quarter and will be delivered upon completion of board service or earlier upon a change in control. After this transaction, the reporting person beneficially owns 74,811 shares of common stock indirectly through the J. Michael Losh Irrevocable Qualified Annuity Trust #7. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Losh and filed on 10/02/2025.
Amesite Inc. (AMST) reported a net loss of approximately $3,617,000 for the fiscal year ended June 30, 2025 and had stockholders' equity of about $2,739,000 on that date. The company had 4,572,713 shares outstanding at June 30, 2025 versus 2,542,440 a year earlier, reflecting recent equity issuances. Amesite completed a public offering of 1,201,667 shares at $3.00 per share, generating approximately $3.6 million gross and about $3.1 million net proceeds, with direct offering costs of $1,164,050 deducted from equity.
The company recorded a $90,869 impairment of capitalized software after discontinuing a higher ed/professional learning app to focus on its NurseMagic app, and recognized warrants issued in connection with underwriting with a fair value of approximately $95,984. Revenues show customer concentration: one line notes 41% of revenues from a single source and that five customers accounted for 97% of 2024 revenue. Cash, cash equivalents and restricted cash of about $2,433,000 are reported.
Amesite (Nasdaq: AMST) filed an 8-K on June 26 2025 announcing a change in its independent auditor.
The Audit Committee dismissed Turner, Stone & Company, whose FY 2024 report contained a going-concern paragraph, and appointed Novogradac & Company effective June 24 2025.
- No disagreements with the former auditor were reported.
- Previously disclosed material weaknesses in internal controls over journal entries, stock-based compensation and deferred revenue remain a reportable event.
- Turner Stone’s concurrence letter is filed as Exhibit 16.1.
The auditor switch may influence audit timelines, remediation efforts and investor perception of financial reporting quality.
FAQ
What is the current stock price of Amesite (AMST)?
What is the market cap of Amesite (AMST)?
